Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

Clinical trial NCT00065156 · COMPLETED

Trial details

NCT number: NCT00065156
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndromes

Start date: 2003-06-01
Primary completion: 2008-08-01
Enrollment: 148

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.